Tirzepatide (Zepbound) came out on top against semaglutide (Wegovy) for treating obesity in the head-to-head SURMOUNT-5 trial ...

The obesity drug helped people trim about two inches more off their waists than Wegovy in the first head-to-head study of the ...

A new study has found that people taking Eli Lilly's obesity drug Zepbound lost almost 50% more weight than those using Novo ...

Eli Lilly said on Sunday its drug Zepbound was superior to Novo Nordisk's Wegovy across five weight-loss targets such as ...

Clinical trial participants who took tirzepatide, the drug sold as Zepbound, lost an average of 50 pounds (22.8 kilograms) ...

In addition to eliciting greater weight loss than Novo Nordisk’s Wegovy, Eli Lilly’s Zepbound does not come at the expense of ...

There were a few anecdotal reports of blood clots in patients whose treatment was interrupted ... Ozempic, Zepbound and Mounjaro to treat obesity, experts say the choices are not so simple.

Eli Lilly & Co.’s obesity drug Zepbound helped people trim about two inches more off their waists than Novo Nordisk A/S’s ...

Novo Nordisk (NYSE: NVO) has entered into a collaboration and licensing agreement with U.S.-based biotech firm Septerna ...

The trial also showed that treatment with Zepbound achieved a superior average ... was lower than in a 2021 trial with similar dose. "Obesity is about more than just a number on a scale," Novo ...

Eli Lilly & Co.’s obesity drug Zepbound helped people trim about two ... of the shot and slightly more Wegovy patients stopped treatment because of side effects such as nausea and vomiting.